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Abstract
GATA3 is a transcription factor important in the differentiation of breast epithelia, urothelia, and
subsets of T-lymphocytes. It has been suggested useful in the evaluation of mammary or urothelial
origin or metastatic carcinomas, but its distribution in normal and neoplastic tissues is
incompletely mapped. In this study, we examined normal developing and adult tissues in 2040
epithelial and 460 mesenchymal or neuroectodermal neoplasms for GATA3 expression to explore
its diagnostic value in surgical pathology, using monoclonal antibody (clone L50-823) and Leica
Bond automated immunohistochemistry. GATA3 was expressed in trophoblast, fetal and adult
epidermis, adult mammary and some salivary gland and sweat gland ductal epithelia, urothelia,
distal nephron in developing and adult tissues, some prostatic basal cells, and subsets of T-
lymphocytes. It was expressed stronger in fetal than adult mesothelia and was absent in respiratory
and gastrointestinal epithelia. In epithelial neoplasms, GATA3 was expressed in >90% of primary
and metastatic ductal and lobular carcinomas of the breast, urothelial, and cutaneous basal cell
carcinomas, and trophoblastic and endodermal sinus tumors. In metastatic breast carcinomas, it
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was more sensitive than GCDFP. Among squamous cell carcinomas, the expression was highest in
the skin (81%) and lower in cervical (33%), laryngeal (16%) and pulmonary tumors (12%).
Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary
gland (43%) and pancreatic (37%) ductal carcinomas, whereas frequency of expression in
adenocarcinomas of lung, stomach, colon, endometrium, ovary, and prostate was <10%.
Chromophobe renal cell carcinoma was a unique renal tumor with frequent positivity (51%),
whereas oncocytomas were positive in 17% of cases but other types only rarely. Among
mesenchymal and neuroectodermal tumors, paragangliomas were usually positive, which sets
these tumors apart from epithelial neuroendocrine tumors. Mesenchymal tumors were only
sporadically positive, except epithelia of biphasic synovial sarcomas. GATA3 is a useful marker in
characterization not only mammary and urothelial but also for renal and germ cell tumors,
mesotheliomas, and paragangliomas. The multiple specificities of GATA3 should be taken into
account when using this marker to detect metastatic mammary or urothelial carcinomas.
Keywords
GATA3; breast cancer; urothelial cancer; choriocarcinoma; endodermal sinus tumor;
chromophobe renal carcinoma; mesothelioma; immunohistochemistry
INTRODUCTION
GATA3 binding protein, commonly and from here on abbreviated as GATA3, is a
transcription factor of the GATA family. These nuclear proteins recognize G-A-T-A
nucleotide sequences in target gene promoters and activate or repress those genes. 1,2
GATA3 function is known to be important in the regulation of genes such as MUC1/EMA
involved in the luminal differentiation of breast epithelium 3 and genes related to T-cell
development. 4,5 Other known functions include gene regulation in the development or
maintenance of skin, especially hair shafts 6,7, trophoblast 8-10 and some endothelial cells,
especially in the great vessels. 11 Constitutional allelic loss of GATA3 (haploinsufficiency)
causes a syndrome characterized by hypoparathyroidism, sensoneurial deafness and renal
malformations, abbreviated as HDR based on these manifestations.12
GATA3 has been thus far explored in surgical pathology as a marker for breast and
urothelial carcinomas. Most primary and metastatic mammary carcinomas express GATA3
(80-90%), but the expression is reportedly lower in triple-negative tumors (67%). 13 In one
study, 82% of female breast carcinomas but only 32% of male breast carcinomas were
GATA3-positive. 14 GATA3 expression seems to be more extensive in lower grade tumors
and positive cases, and cases with high expression may have a better survival 14,15 However,
none of those studies have assessed the specificity of GATA3 for breast cancer. In another
study, strong expression of GATA3 (in >50% tumor cells) was detected only in mammary
(94%), urothelial (86%), and endometrial (2%) adenocarcinomas, but in none of the
pulmonary, pancreatic, colonic, prostatic, and ovarian carcinomas in a relatively small
sample. 16
GATA3 was discovered as a urothelial carcinoma marker by CDNA expression
microarrays 17 and found downregulated in invasive bladder cancers.18 Since then it has
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been suggested useful in the distinction between urothelial vs. prostatic adenocarcinoma and
metastatic urothelial vs. squamous cell carcinoma in the lung, with 80% of metastatic
urothelial carcinomas but none of the pulmonary squamous cell carcinomas or high-grade
prostatic carcinomas being positive. 19 In another study, 78% primary invasive urothelial
carcinomas and 23% pulmonary squamous cell carcinomas were positive indicating a lesser
specificity. 20 Also, transitional cell lesions of ovaries, such as Brenner tumors, have been
found as GATA3-positive. 21
In this study we immunohistochemically examined 2500 epithelial and mesenchymal or
neuroectodermal tumors for GATA3 to further explore its specificity for mammary and
urothelial carcinomas and evaluated its other specificities potential applicable in surgical
pathology.
MATERIALS AND METHODS
The tumors and normal tissues were obtained from surgical specimens and arranged in
multitissue blocks containing 5-50 cases as previously described. 22 A total of 2040
epithelial neoplasms and 460 mesenchymal and neuroectodermal tumors were examined. In
addition, we evaluated a spectrum of normal human adult, fetal, and embryonic tissues from
surgical specimens. Lymphomas and related tumors were excluded from the study.
The primary antibody to GATA3 (Clone L50-823) was obtained from Biocare Medical,
Concord, CA. The antibody was used in a dilution of 1:500. Immunohistochemical analysis
was performed in a Leica Bond Max automated immunostainer (Leica, Bannockburn, IL).
High-pH epitope retrieval buffer was used for 25 minutes prior to application of the primary
antibody (30 min.). Detection was performed using Leica Bond-detection kit with
diaminobenzidine as the chromogen, followed by a light hematoxylin counterstain. Tumor-
infiltrating or peritumoral lymphocytes were used as internal controls and renal distal
tubules and collecting ducts as external positive controls. Only nuclear staining was scored
and the percentage of positive nuclei was estimated. However, cytoplasmic staining was an
infrequent finding and such staining was usually weak. Intensity of staining was generally
strong and was not scored separately. Tumors studied here were previously extensively
characterized with relevant markers.
Metastatic breast cancers were also evaluated for GCDFP-15 (mouse monoclonal antibody,
clone D6 from Signet, Dedham, MA, diluted at 1:40, staining preceded by 4 min digestion
with Ventana protease 1, primary antibody incubated for 32 min.) and all trophoblastic
tumors/components for beta HCG (Dako Cytomation, diluted 1:60000, staining preceded by
heat retrieval in a steamer in 1mM EDTA buffer, pH 9, primary antibody incubated for 2
hrs). Both latter antibodies were tested using Ventana Benchmark automation using the
Ultra View detection kit (Ventana Medical Systems, Tucson, AZ). The GATA3-negative
urothelial carcinomas were also examined for thrombomodulin/CD141 using a Novocastra/
Leica antibody (diluted 1:100), with detection performed by Leica automated
immunohistochemistry as described above.
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In a 7th week embryo, strong nuclear GATA3-positivity was detected in the epidermis,
peritoneal mesothelia, virtually all trophoblastic cells, and amnion epithelia (Fig. 1 A-C).
Distinct focal positivity was also detected in the caudal mesenchyme and in some
endothelial cells in the great vessels adjacent to the heart. Negative were spinal nervous and
muscle tissue, liver, heart muscle, primordia of lung and intestines, mesenchyme in general,
and the yolk sac.
In a 10th week fetus, epidermis (especially basal portion), epithelia of oral cavity, olfactory
plate, periocular mesenchyme, cartilage of the skull base, isolated cells in the brain, and
nerve ganglia showed positivity. In the kidney, approximately 1/3 of the tubular structures
and glomerular mesangial cells were positive (Fig. 1 D). Choroid plexus, eye, liver, and
intestines were negative.
Normal adult tissues
Strong nuclear GATA3-positivity was detected in the epidermis, sebaceous epithelia, and
hair shafts (Fig. 2A). Eccrine sweat glands were focally and apocrine glands extensively
positive. Uterine ectocervical squamous epithelium was variably positive. Lobular and
ductal epithelia of the breast and nipple were positive, but myoepithelial cells were negative
(Fig. 2 B). Urothelial epithelia of the renal pelvis, ureter, and urinary bladder were strongly
positive (Fig. 2 C). In the kidney, other positive elements included collecting ducts, distal
tubules, and mesangial cells (Fig. 2D). Seminal vesicle epithelia were positive, and prostatic
basal cells variably positive and luminal cells typically negative. Terminal ducts of normal
parotid and small ducts in atrophic glands were extensively positive. In the lymphoid tissue
of tonsil, only scattered germinal center cells and interfollicular T-cells were positive, but
the thymic cortex contained large numbers of positive thymocytes. Omental peritoneal
mesothelium was negative, but positivity was detected in reactive mesothelia.
Negative were thyroid, respiratory and pulmonary alveolar epithelia, gastric and intestinal
mucosae and mesenchyme, hepatocytes, bile ducts, gallbladder, exo- and endocrine
pancreas, testicular seminiferous tubules, Leydig cells of testis, and ovarian stroma. In the
endometrium, glands were negative. However, decidual stromal change in the uterus and
extra-uterine endometriosis were positive. The latter was evaluated as a non-trophoblast
containing tissue.
Epithelial neoplasms
The results on epithelial neoplasms have been summarized in Table 1 and the description
below is centered on positive results.
A great majority of primary ductal carcinomas of the breast (163/178, 92%), and their
metastases (49/51, 96%) including 30 from lymph nodes, 10 from brain (Fig. 3 A, B), and 9
from other sites, were positive. Great majority of cases showed positivity in all tumor tumor
cells. All but two negative examples were high-grade ductal carcinomas and all but one of
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the negative examples tested were also estrogen receptor (ER)-negative (6/7). However,
30/36 of ER-negative ductal carcinomas were GATA3-positive, but they often showed
heterogeneous, reduced GATA3-expression, which however exceeded 50% of positive
tumor cells in 23/36 cases. The 4 triple-negative cancers (values of ER, PR, and HER2 = 0)
had GATA3 expression in 40-70% of tumor cells. However, if <5% of ER, PR, or HER2
was accepted as triple negative, there were 1/13 cases negative for GATA3 and 4 showing
reduced < 50% positivity. In a cohort of 37 metastatic ductal carcinomas tested for both
markers, GATA3 was more sensitive than GCDFP-15 (92 vs. 78% for overall positivity) and
often showed a higher number of positive cells (median values 100% vs. 30%).
All 31 lobular carcinomas of the breast, including 4 metastases, 10 mucinous, and 1
papillary carcinoma of the breast were also positive, but 4/10 mucinous carcinomas showed
reduced GATA3-positivity (<50% of tumor cells positive). A metastatic mammary lobular
carcinoma in the small intestine was highlighted as a rare GATA3-positive intestinal
neoplasm (Fig. 3 C, D).
Most urothelial carcinomas (49/54) were extensively positive, except 5 tumors, which were
either poorly differentiated or showed prominent squamous differentiation. All three
negative tumors that were studied were also negative for thrombomodulin.
Of skin tumors, cutaneous squamous cell carcinomas were usually positive, 81%, with a
median of 50% tumor cells positive (range, 5-100%) (Fig. 4 A). In comparison, other
squamous cell carcinomas were less commonly positive: cervical carcinomas (33% of cases,
nearly half of them showing positivity in >50% of tumor cells). Laryngeal (16%) and
pulmonary ones (12%) were less commonly positive. However, half of the GATA3-positive
examples of the pulmonary tumors and 2 of 8 of the laryngeal ones showed positivity in >
50% of tumor cells.
Nearly all cutaneous basal cell carcinomas were strongly and uniformly positive. Similarly
positive were trichoepitheliomas, basaloid cells of pilomatricoma, epithelia of pilar cyst, and
seborrhoic keratosis (4 cases of each studied). Focal epithelial cell positivity was seen in
mixed tumors of the skin, cylindroma, eccrine spiradenoma, and hidradenoma/eccrine
acrospiroma (2 of each studied).
Salivary gland and pancreatic ductal adenocarcinomas were the most commonly GATA3-
positive non-mammary adenocarcinomas (43% and 37% of cases positive). The salivary
gland ductal carcinomas had 100% of positive cells in 4 cases, 60% in one case, and 20% in
the remaining case. The positive pancreatic carcinomas included non-mucinous (Fig. 4B)
and mucinous adenocarcinomas. The number of positive cells varied from 10-100%
(median, 25%). One sweat gland carcinoma was also strongly positive similar to breast
cancers.
Among renal carcinomas, chromophobe carcinomas showed a high frequency (51%) of
GATA3-positivity (Fig. 4 C), and this was typically extensive and detected in the majority
of tumor cells. Oncocytomas were less commonly positive (17%), but also had high
numbers of positive nuclei and additionally displayed some cytoplasmic labeling (Fig. 4 D).
Two oncocytoma-chromophobe carcinoma hybrid tumors showed variable positivity in
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10-20% of tumor cells. In clear cell carcinomas, positivity was rare (<2%). One of the other
positive tumors was a type 2 papillary renal carcinoma, whereas all 15 type 1 papillary
carcinomas were negative.
Over half (58%) of malignant mesotheliomas showed nuclear GATA3-positivity. Positivity
was detected in both epithelial and sarcomatoid mesotheliomas (Fig. 5). The number of
positive cells varied but most positive cases showed a high percentage of positive cells
(range: 10-100%, median: 75%).
In germ cell tumors, GATA3 positivity was consistently detected in pure choriocarcinomas
and choriocarcinoma components of mixed germ cell tumors also shown positive for beta
HCG, and in a placental site trophoblastic tumor involving myometrium (Fig. 6 A, B). Also,
syncytiotrophoblastic giant cells that were present in 2 seminomas and verified beta HCG-
positive were positive for GATA3, whereas seminoma cells were negative in all cases (Fig.
6 C). Endodermal sinus tumors seen as the pure type or as a component of a mixed germ cell
tumor were strongly GATA3 positive (Fig. 6 D). Embryonal carcinoma cells were generally
negative. However, some embryonal carcinomas contained GATA3-positive focal elements
that included thin layers of cuboidal epithelioid cells surrounding embryoid bodies and
additionally focal cell clusters in some cases.
GATA3-positivity was rare in adenocarcinomas of the lung (6/71). The positive cases were
3 poorly differentiated tumors containing 40-60% of positive cells, 2 mucinous
adenocarcinomas with 30 and 60% of positive cells, and one papillary adenocarcinoma with
<5% of GATA3-positive cells.
The frequency of GATA3-positivity in carcinomas of stomach, colon, prostate,
endometrium, ovary and thyroid did not exceed 7% in any of the above mentioned
categories. The percentage of positive cells was 5-30% with the exception of one
endometrial and one gastric carcinoma, in which 100% of tumor cells were positive. All
gastric signet ring cell carcinomas were negative.
All epithelial neuroendocrine tumors including low-grade tumors such as carcinoids and
well-differentiated pancreatic neuroendocrine tumors, and high-grade neuroendocrine
carcinomas, such as pulmonary small cell and Merkel cell carcinomas, were negative.
Epithelial components of thymomas were negative but GATA3-positive T-lymphocytes
were variably present, especially in type B1 thymomas.
Mesenchymal and neuroectodermal tumors
The results on mesenchymal or neuroectodermal tumors have been summarized in Table 2.
Exceptionally prominent GATA3-positivity was detected in pheochromocytoma and extra-
adrenal paraganglioma that were GATA3-positive in most cases (>80%) and usually had
positivity in >50% of tumor cells. In biphasic synovial sarcoma, glandular epithelial
component showed GATA3-positivity in 4/5 cases, whereas only one poorly differentiated
spindle cell variant was focally positive. Three of 17 epithelioid sarcomas were also
positive.
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Other mesenchymal tumors were only sporadically positive (< 10% of cases in each
category). There were examples of myxofibrosarcomas/undifferentiated sarcomas, poorly
differentiated angiosarcomas, leiomyosarcomas, and malignant peripheral nerve sheath
tumors with focal to extensive nuclear GATA3-positivity. In these categories it was not
possible to identify specific features that correlated with GATA3-positivity. All metastatic
melanomas and clear cell sarcomas were negative.
DISCUSSION
GATA3 is a multifunctional transcription factor especially linked in the development and
function of ductal epithelial cells of breast, urothelia, epidermis, some skin adenxa, and
subsets of T-cells. 1-10 In this study we immunohistochemically mapped GATA3 expression
in developing, normal adult, and neoplastic tissues to obtain understanding of its distribution
and further evaluate its specificity for its common detection targets, mammary and urothelial
carcinomas. Furthermore, we explored other potential applications for GATA3
immunohistochemistry in surgical pathology by screening a large number of epithelial and
non-epithelial neoplasms.
Despite its complex distribution in epithelial tumors, GATA3 is potentially useful in several
specific settings. Strong nuclear labeling obtained with a new monoclonal antibody to
GATA3 (Clone L50-823) that is easy to interpret is an additional factor increasing the
diagnostic value of this marker. In normal tissues, this antibody yielded similar results as
previously noted for breast 3, skin 7, kidney 5, endothelia of great vessels 10, and subsets of
lymphocytes 4, which in part validates the used antibody. Presence of GATA3-positive
tumor-associated T-lymphocytes also serves as a nearly universal internal control useful in
technically validating individual cases.
In the breast, GATA 3 is mainly expressed in luminal epithelia and it has been reported
frequently expressed in breast carcinomas and as a potential marker for mammary origin of
metastatic carcinoma.13-16 In this study, GATA3 was detected in 92% of primary ductal
carcinomas of the breast. Furthermore, it was retained with a high percentage (96%) in
metastatic breast cancers. Retention of GATA3 in most metastatic carcinomas makes this
marker useful in evaluating metastatic carcinomas, especially when presenting in unusual
sites. The frequency of GATA3-positivity found in this study is approximately similar if not
higher than that reported in previous studies (80-90%). 14-16
GATA3 was also present in most urothelial carcinomas, but was absent in some high-grade
examples. In terms of sensitivity, the findings are similar to a previous study (>80%). 19
GATA3 expression in seminal vesicle epithelia should be taken into account when using this
marker in cytologic specimens suspected of urothelial carcinoma. In the differential
diagnosis of urothelial vs. pulmonary squamous cell carcinoma one has to consider that
some cases of the latter can have a strong GATA3-expression in a majority of tumor cells,
so that such positivity is not specific for urothelial carcinoma.
Beyond mammary and urothelial carcinomas, commonly GATA3-positive carcinomas based
on this study are basal cell carcinoma (98%), cutaneous squamous cell carcinoma (75%),
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skin adnexal tumors, malignant mesothelioma (58%), chromophobe carcinoma of the kidney
(51%), and ductal carcinomas of salivary gland (43%) and pancreas (37%). In the latter,
GATA3 protein expression seems to parallel common expression of GATA3-specific RNA,
as previously detected in pancreatic carcinoma. 23 Expression of GATA3 in the above
mentioned tumors has to be considered when using this marker to identify mammary or to so
degree, urothelial carcinomas, especially in small biopsies or cytologic specimens, in which
immunohistochemical findings may have a greater role in diagnosis.
High GATA3-expression in cutaneous squamous cell carcinomas parallels GATA3
expression in developing and adult epidermis. 6,7 Because GATA3 is markedly less
commonly detected in cervical, laryngeal, and pulmonary squamous cell carcinomas,
GATA3 may have some value in evaluating cutaneous vs. other origin for a squamous cell
carcinoma.
In renal cell carcinomas, GATA 3 was expressed in over half of chromophobe carcinomas,
while its expression was notably rare in other carcinoma types (<2%), so that GATA3 is of
interest in subtyping of renal carcinomas. Also, 2 hybrid chromophobe carcinoma-
oncocytoma tumors considered related to chromophobe carcinoma and often occurring in
Birt-Hogg-Dubé syndrome 24 were focally GATA3-positive. GATA3-positivity of
chromophobe carcinomas and oncocytomas seems to be a new parameter linking these
tumors with the distal nephron, which is also GATA3-positive. Older studies considered
both of these tumors potentially histogenetically related with the intercalated cells of
collecting ducts. 25,26 Electron microscopic studies showed oncocytomas to share distal
tubular character in their content of short microvilli. 27 A more recent observation also
linking both chromophobe carcinoma and renal oncocytoma with distal nephron is their
expression of kidney-specific cadherin 28
Choriocarcinomas are strongly GATA3 positive mirroring the fetal trophoblastic phenotype.
In addition, GATA3 labels strongly endodermal sinus tumors, but is absent in seminomas
and embryonal carcinoma cells, with exceptional expression around embryoid bodies.
However, the latter are believed to have endodermal sinus tumor differentiation29, which
seems to explain their GATA3-positivity. Based on these observations, GATA3 can be
useful tool in the subtyping of germ cell tumors and especially highlighting trophoblastic
and endodermal sinus tumor-like differentiation. A caveat in using GATA3 to identify
trophoblasts in the context of uterine tissues is its expression also in decidual stromal cells,
as seen in endometrium and extra-uterine endometriosis.
Carcinomas with very infrequent GATA3-expression include pulmonary, gastrointestinal,
ovarian and prostatic adenocarcinomas, and adrenocortical and thyroid carcinomas. Rare
GATA3-expression in these tumors facilitates detection of metastatic mammary or urothelial
carcinomas in those sites. More studies are required to determine biologic significance of the
rare GATA3-positive subsets of the above mentioned carcinomas.
Mesenchymal and neuroectodermal tumors of various types generally showed a low
frequency of GATA3 expression. An exception was paraganglioma (both adrenal and extra-
adrenal), which were positive in >80% of cases. GATA3 may therefore have value in
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separating paragangliomas and epithelial neuroendocrine tumors, as the latter are uniformly
negative, as recently reported. 30
There is little information on GATA3 expression in sarcomas. In this study, glandular
elements of biphasic synovial sarcoma were usually positive, and 20% of epithelioid
sarcomas were variably positive indicating that GATA3-positivity may reflect epithelial
differentiation in mesenchymal tumors. In most groups of other sarcomas, 0-10% of cases
showed positivity. However, GATA3 is mentioned as gene expressed in MFH/
undifferentiated pleomorphic sarcoma by RNA-expression array studies and suggested as an
adverse prognostic factor based on a small cohort. 31
In summary, we examined immunohistochemically a large number of epithelial and
mesenchymal tumors for GATA 3. This marker is a sensitive although not totally specific
for mammary and urothelial carcinomas. Commonly GATA3 positive other epithelial
tumors include basal cell carcinoma, cutaneous squamous cell carcinoma, skin adnexal
tumors, choriocarcinoma, endodermal sinus tumor, renal chromophobe carcinoma,
malignant mesothelioma, and salivary gland and pancreatic ductal adenocarcinoma. In
addition, GATA3 is expressed with a lower frequency (generally <10%) in a wide variety of
carcinomas. However, GATA3 is rarely expressed in neuroectodermal and mesenchymal
tumors, except in pheochromocytoma/paraganglioma, which helps to distinguish the latter
from neuroendocrine carcinomas. Despite its multispecificity, GATA3 is a potential tool for
characterization of carcinomas and selected mesenchymal and neuroectodermal tumors.
Table 3 outlines potential diagnostic applications of GATA3 showing contrasting pairs of
expectedly positive and negative tumors.
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GATA3 expression in embryonic tissues. A 7-week embryo shows GATA3-positivity in
trophoblast (A), peritoneal mesothelium (B), and skin (C). A 10-week fetus shows GATA3
expression in some renal tubuli and the glomerular mesangium (D).
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GATA3 expression in adult tissue. A. Epidermal cells are positive. Note also positive
dermal lymphocytes. B. Luminal cells of ducts of a breast lobule a positive, whereas
myoepithelial cells are negative. C. Ureteral epithelium and some stromal lymphocytes are
positive. D. Distal tubular epithelial and mesangial cells are GATA3-positive.
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Two examples of GATA3-positive metastatic breast cancers. A, B. A ductal carcinoma with
apocrine features metastatic to the brain is strongly positive. C, D. Lobular carcinoma
metastatic to small intestine in highlighted as GATA3-positive.
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A. Examples of GATA3-positive epithelial neoplasms. Strong expression in cutaneous
squamous cell carcinoma B. Pancreatic ductal adenocarcinoma cells show nearly uniform
labeling. C. Renal chromophobe carcinoma cells are positive. D. Most cells of renal
oncocytoma are positive and there is also weak cytoplasmic labeling.
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A malignant epithelial mesothelioma with a pseudoglomerular formation within a
tubulopapillary pattern shows strong GATA3-positivity.
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GATA3 expression in germ cell tumors. A. Choriocarcinomas were strongly positive. B.
Myometrial invasion of placental site trophoblastic tumor is positive. C. Seminomas are
negative, but isolated syncytiotrophoblastic cells are highlighted. D. Endodermal sinus
tumor with Schiller-Duval body in the center is strongly positive.
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Table 1
Expression of GATA3 in 2040 epithelial neoplasms.
Tumor type Positive/total % positive
Adrenocortical carcinoma 3/27 (11)
Basal cell carcinoma, skin 61/62 (98)
Benign skin adnexal tumors (see text) 24/24 (100)
Breast, ductal carcinoma, primary 164/179 (92)
Breast, ductal carcinoma, metastatic 49/51 (96)
Breast, lobular carcinoma 38/38 (100)
Colon, adenocarcinoma 2/142 (1)
Endometrium, adenocarcinoma 6/89 (7)
Germ cell tumor, seminoma 0/76
Germ cell tumor, choriocarcinoma 11/11 (100)
Germ cell tumor, endodermal sinus tumor 6/6 (100)
Germ cell tumor, pure embryonal carcinoma 0/5* (40)
Liver, hepatocellular carcinoma 1/47 (2)
Liver, Cholangiocarcinoma 5/57 (9)
Lung, adenocarcinoma 6/71 (8)
Lung, small cell carcinoma 0/30
Lung, carcinoid 0/11
Small, intestine, carcinoid 0/18
Malignant mesothelioma 37/64 (58)
Merkel cell carcinoma 0/4
Ovary, serous carcinoma 4/73 (6)
Ovary, other carcinomas 0/25
Pancreas, adenocarcinoma 23/62 (37)
Pancreas, neuroendocrine tumor 0/15
Prostate, adenocarcinoma 2/95 (2)
Rectum, adenocarcinoma 0/27
Renal cell carcinoma, chromophobe 18/35 (51)
Renal oncocytoma 6/35 (17)
Renal cell carcinoma, other than chromophobe 3/154 (2)
Salivary gland, adenoid cystic carcinoma 5/17 (29)
Salivary gland, ductal carcinoma 6/14 (43)
Squamous cell carcinoma, skin 25/31 (81)
Squamous cell carcinoma, cervix 7/21 (33)
Squamous cell carcinoma, larynx 8/36 (16)
Squamous cell carcinoma, lung 9/74 (12)
Stomach, adenocarcinoma 6/133 (5)
Thymoma 0/41
Thyroid, papillary carcinoma 3/55 (5)
Thyroid, follicular carcinoma 1/20 (5)
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Tumor type Positive/total % positive
Thyroid, anaplastic carcinoma 1/11 (9)
Urothelial carcinoma, low-grade 22/22 (100)
Urothelial carcinoma, high-grade 27/32 (84)
*
Majority of tumor cells negative, small positive subpopulations of uncertain nature detected in some cases.
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Table 2
Expression of GATA3 in 460 mesenchymal and neuroectodermal neoplasms
Angiosarcoma 2/30
Clear cell sarcoma 0/18
Epithelioid sarcoma 3/17
Fibrothecoma of ovary 0/14
Gastrointestinal stromal tumor, stomach 0/24
Granulosa cell tumor of ovary 0/19
Kaposi sarcoma 0/25
Leiomyosarcoma, soft tissue (non-visceral) 5/59








Expressed in glands of 4 biphasic tumors and one poorly differentiated spindle cell tumor.
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Table 3
Potential discriminatory value of GATA3 immunohistochemistry in tumor diagnosis –examples of contrasting
pairs of tumors with potential morphologic mimicry.
Positive tumors Negative tumors
Metastatic lobular carcinoma
of the breast Gastric/intestinal signet ring cell carcinoma
Metastatic ductal carcinoma Pulmonary/gastrointestinal/ovarian
carcinoma
Urothelial carcinoma Prostate carcinoma
Squamous carcinoma of skin origin Squamous carcinoma of pulmonary origin
Malignant mesothelioma Pulmonary adenocarcinoma
Pancreatic adenocarcinoma Gastrointestinal adenocarcinomaCholangiocarcinoma
Chromophobe renal carcinoma Clear cell renal carcinoma
Endodermal sinus tumor
Choriocarcinoma Embryonal carcinoma, Seminoma
Paraganglioma Neuroendocrine carcinoma
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